These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

499 related articles for article (PubMed ID: 28422425)

  • 1. Negativization of viremia prior to liver transplant reduces early allograft dysfunction in hepatitis C-positive recipients.
    Martini S; Tandoi F; Terzi di Bergamo L; Strona S; Lavezzo B; Sacco M; Maione F; Gonella F; Strignano P; Dell Olio D; Salizzoni M; Saracco GM; Romagnoli R
    Liver Transpl; 2017 Jul; 23(7):915-924. PubMed ID: 28422425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Early Allograft Function Using the Liver Graft Assessment Following Transplantation Risk Score Model.
    Agopian VG; Harlander-Locke MP; Markovic D; Dumronggittigule W; Xia V; Kaldas FM; Zarrinpar A; Yersiz H; Farmer DG; Hiatt JR; Busuttil RW
    JAMA Surg; 2018 May; 153(5):436-444. PubMed ID: 29261831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting early allograft failure and mortality after liver transplantation: the role of the postoperative model for end-stage liver disease score.
    Wagener G; Raffel B; Young AT; Minhaz M; Emond J
    Liver Transpl; 2013 May; 19(5):534-42. PubMed ID: 23576469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of a current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factors.
    Olthoff KM; Kulik L; Samstein B; Kaminski M; Abecassis M; Emond J; Shaked A; Christie JD
    Liver Transpl; 2010 Aug; 16(8):943-9. PubMed ID: 20677285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-Liver Transplant Early Allograft Dysfunction Modifies the Effect of Pre-Liver Transplant Renal Dysfunction on Post-Liver Transplant Survival.
    Wadei HM; Keaveny AP; Taner CB; Yang L; Mai ML; Hodge DO; White LJ; Mao SA; Jarmi T; Croome KP
    Liver Transpl; 2021 Sep; 27(9):1291-1301. PubMed ID: 33687745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early allograft dysfunction after liver transplantation: an intermediate outcome measure for targeted improvements.
    Lee DD; Croome KP; Shalev JA; Musto KR; Sharma M; Keaveny AP; Taner CB
    Ann Hepatol; 2016; 15(1):53-60. PubMed ID: 26626641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver transplant recipients and prioritization of anti-HCV therapy: an Italian cohort analysis.
    Lanini S; Nanni Costa A; Grossi PA; Procaccio F; Ricci A; Capobianchi MR; Terrault NA; Ippolito G
    Liver Int; 2016 Mar; 36(3):410-7. PubMed ID: 26264452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors, surgical complications and graft survival in liver transplant recipients with early allograft dysfunction.
    Bastos-Neves D; Salvalaggio PRO; Almeida MD
    Hepatobiliary Pancreat Dis Int; 2019 Oct; 18(5):423-429. PubMed ID: 30853253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing repeat liver transplant graft utility through strategic matching of donor and recipient characteristics.
    Hung K; Gralla J; Dodge JL; Bambha KM; Dirchwolf M; Rosen HR; Biggins SW
    Liver Transpl; 2015 Nov; 21(11):1365-73. PubMed ID: 25865434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of direct-acting antiviral agents on liver and kidney transplant costs and outcomes.
    Axelrod DA; Schnitzler MA; Alhamad T; Gordon F; Bloom RD; Hess GP; Xiao H; Nazzal M; Segev DL; Dharnidharka VR; Naik AS; Lam NN; Ouseph R; Kasiske BL; Durand CM; Lentine KL
    Am J Transplant; 2018 Oct; 18(10):2473-2482. PubMed ID: 29701909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should a lower quality organ go to the least sick patient? Model for end-stage liver disease score and donor risk index as predictors of early allograft dysfunction.
    Croome KP; Marotta P; Wall WJ; Dale C; Levstik MA; Chandok N; Hernandez-Alejandro R
    Transplant Proc; 2012 Jun; 44(5):1303-6. PubMed ID: 22664005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Temporal Changes and Regional Variation in Acceptance of Hepatitis C Virus-Viremic Livers.
    Mazur RD; Goldberg DS
    Liver Transpl; 2019 Dec; 25(12):1800-1810. PubMed ID: 31539195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes following liver transplantation from HCV-seropositive donors to HCV-seronegative recipients.
    Aqel B; Wijarnpreecha K; Pungpapong S; Taner CB; Reddy K; Leise M; Mi L; Dickson RC
    J Hepatol; 2021 Apr; 74(4):873-880. PubMed ID: 33188903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utilization of hepatitis C viremic donors for liver transplant recipients without hepatitis C. A veterans transplant center report.
    Said A; Weiss M; Varhelyi A; Farago R; Ballweg C; Rice J; Agarwal P; Fernandez L; Foley D
    Transpl Infect Dis; 2021 Apr; 23(2):e13466. PubMed ID: 32931616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increasing Utilization and Excellent Initial Outcomes Following Liver Transplant of Hepatitis C Virus (HCV)-Viremic Donors Into HCV-Negative Recipients: Outcomes Following Liver Transplant of HCV-Viremic Donors.
    Cotter TG; Paul S; Sandıkçı B; Couri T; Bodzin AS; Little EC; Sundaram V; Charlton M
    Hepatology; 2019 Jun; 69(6):2381-2395. PubMed ID: 30706517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clearance of hepatitis C virus after living-donor liver transplantation in spite of residual viremia on end date of interferon therapy before transplantation.
    Ichikawa T; Nakao K; Hamasaki K; Honda T; Shibata H; Akahoshi M; Eguchi S; Takatsuki M; Kanematsu T; Eguchi K
    World J Gastroenterol; 2007 Aug; 13(30):4149-51. PubMed ID: 17696240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of early allograft dysfunction on outcomes following liver transplantation.
    Hudcova J; Scopa C; Rashid J; Waqas A; Ruthazer R; Schumann R
    Clin Transplant; 2017 Feb; 31(2):. PubMed ID: 28004856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the updated definition of early allograft dysfunction in donation after brain death and donation after cardiac death liver allografts.
    Croome KP; Wall W; Quan D; Vangala S; McAlister V; Marotta P; Hernandez-Alejandro R
    Hepatobiliary Pancreat Dis Int; 2012 Aug; 11(4):372-6. PubMed ID: 22893463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreasing Significance of Early Allograft Dysfunction with Rising Use of Nonconventional Donors.
    Ohara S; Macdonough E; Egbert L; Brooks A; Lizaola-Mayo B; Mathur AK; Aqel B; Reddy KS; Jadlowiec CC
    Medicina (Kaunas); 2022 Jun; 58(6):. PubMed ID: 35744084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful treatment of fibrosing cholestatic hepatitis after liver transplantation.
    Cimsit B; Assis D; Caldwell C; Arvelakis A; Taddei T; Kulkarni S; Schilsky M; Emre S
    Transplant Proc; 2011 Apr; 43(3):905-8. PubMed ID: 21486625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.